Probiotic Composition Using CKDB001 for NAFLD Gut Microbiota Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional therapies for non-alcoholic fatty liver disease (NAFLD) are often ineffective due to poor compliance, lack of efficacy, or changes in diet and lifestyle, and there is a need for a more effective approach to regulate gut microbiota for therapeutic benefits.
Innovation Solution
A Lactobacillus delbrueckii subsp. lactis CKDB001 strain, combined with Bifidobacterium strains, is used to develop a composition that reduces steatosis and inflammation in NAFLD models by administering a lyophilizate powdered formulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for NAFLD, then treatment coverage is provided, but compliance is poor and efficacy is insufficient
Solution Approach 1:
The patent introduces probiotics (Lactobacillus delbrueckii subsp. lactis and Bifidobacterium strains) as intermediary agents that mediate the treatment effect by regulating gut microbiota composition. These probiotics serve as a biological mediator between the administered composition and the liver, improving therapeutic efficacy through gut-liver axis modulation without requiring strict patient compliance with lifestyle changes
Solution Approach 2:
The patent changes the therapeutic parameter from direct liver intervention to indirect gut microbiota modulation. By administering specific probiotic strains that alter gut microbial composition and metabolism, the treatment achieves therapeutic effects through parameter changes in the gut ecosystem, which then translate to improved liver health outcomes
2Reliability
If diet and lifestyle changes are implemented, then therapeutic benefits may be achieved, but patient compliance is poor due to difficulty of maintenance
Solution Approach 1:
The probiotic composition performs self-service by automatically regulating gut microbiota without requiring continuous patient effort or behavioral changes. Once administered, the probiotic strains establish themselves in the gut ecosystem and continuously provide therapeutic effects, eliminating the need for ongoing lifestyle management by the patient
Solution Approach 2:
The patent applies preliminary action by pre-establishing beneficial probiotic strains in the gut before pathological changes can occur or worsen. This preventive approach addresses the root cause of NAFLD through gut microbiota regulation, eliminating the need for prolonged lifestyle intervention and maintenance
3Reliability
If probiotic composition is administered, then gut microbiota regulation is achieved, but the specific strain combination and dosage optimization is complex
Solution Approach 1:
The patent merges two distinct probiotic genera (Lactobacillus and Bifidobacterium) into a single composite composition, leveraging their synergistic effects. This combination approach simplifies the treatment protocol by providing a ready-to-use multi-strain product that achieves enhanced gut microbiota regulation without requiring patients to take multiple separate supplements
Solution Approach 2:
The probiotic composition exhibits universality by addressing multiple aspects of NAFLD pathogenesis simultaneously - regulating gut microbiota composition, improving gut barrier function, reducing inflammation, and modulating metabolism. This multi-functional approach simplifies the treatment strategy by providing a single intervention with broad therapeutic effects
Data Source
AI summary
The present invention relates to a Lactobacillus lactis CKDB001 strain, and a composition for the prevention or treatment of non-alcoholic fatty liver comprising same. When the composition of the present invention is ingested, the composition has the effect of ameliorating high-fat diet-induced fatty cirrhosis and inflammations caused thereby, and thus the composition of the present invention can be effectively used as a preparation for ameliorating or treating non-alcoholic fatty cirrhosis and steatohepatitis.